Efficacy of Voriconazole in the Treatment of Invasive Pulmonary Fungal Infections in Children

Xu Qianqian; Liu Yan

doi:10.13407/ j.cnki.jpp.1672.108X.2021.09.004

您当前的位置：

首页 >

文章列表页 >

Efficacy of Voriconazole in the Treatment of Invasive Pulmonary Fungal Infections in Children

更新时间：2022-11-03

- Efficacy of Voriconazole in the Treatment of Invasive Pulmonary Fungal Infections in Children
- Vol. 27, Issue 9, Pages: 12-15(2021)
- 作者机构：
  
  华中科技大学同济医学院附属同济医院,湖北,武汉,430030
- 作者简介：
- 基金信息：
- DOI：10.13407/ j.cnki.jpp.1672.108X.2021.09.004
  CLC：
- Published：2021，
扫描看全文
Xu Qianqian, Liu Yan. Efficacy of Voriconazole in the Treatment of Invasive Pulmonary Fungal Infections in Children. [J]. 27(9):12-15(2021)
DOI：

Xu Qianqian, Liu Yan. Efficacy of Voriconazole in the Treatment of Invasive Pulmonary Fungal Infections in Children. [J]. 27(9):12-15(2021) DOI： 10.13407/ j.cnki.jpp.1672.108X.2021.09.004.

摘要

目的：探讨伏立康唑治疗儿童侵袭性肺部真菌感染（IPFI）的临床效果及安全性。方法：收集我院儿科呼吸病房2018年2月至2019年1月收治的IPFI患儿88例，采用随机数表法分为伏立康唑组和米卡芬净组各44例，分别选用伏立康唑和米卡芬净进行治疗，疗程均为4~6周，比较两组患儿的临床疗效与不良反应发生率。结果：伏立康唑组总有效率93.18%，高于米卡芬净组的77.27%；临床症状消退时间、痰培养转阴时间、影像学病灶吸收时间均短于米卡芬净组（P均<0.05），两组不良反应发生率比较差异无统计学意义（P>0.05）。结论：伏立康唑治疗儿童IPFI的临床疗效优于米卡芬净，且用药安全，可作为儿童IPFI的有效抗真菌药物在临床上推广应用。

Abstract

Objective: To probe into the clinical efficacy and safety of voriconazole in the treatment of invasive pulmonary fungal infections (IPFI) in children. Methods: Totally 88 children with IPFI admitted into our hospital from Feb. 2018 to Jan. 2019 were extracted to be divided into the voriconazole group and the micafungin group via the random number table

with 44 cases in each group

voriconazole and micafungin were retrospectively given for treatment of 4 to 6 weeks. Clinical efficacy and incidence of adverse drug reactions were compared between two groups. Results: The total effective rate of the voriconazole group was 93.18%

higher than 77.27% of the control group. The disappearance time of clinical symptoms

the conversion time of sputum culture

and the absorption time of imaging lesions in the voriconazole group were shorter than those in the micafungin group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between two groups (P>0.05). Conclusion: The clinical efficacy of voriconazole in the treatment of children with IPFI is better than that of micafungin

and it is safe to be used as the effective anti-fungal drug for children with IPFI in clinical application.

关键词

侵袭性肺部真菌感染儿童伏立康唑米卡芬净

Keywords

nvasive pulmonary fungal infectionschildrenoriconazolemicafungin

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of Pharmaceutical Care on the Use of Voriconazole in Pediatric Liver Transplantation Patients Younger Than 2 Years of Age

Clinical Application of Therapeutic Drug Monitoring of Voriconazole in Children with Hematological Disease

Analysis of 36 Cases of Drug Poisoning in Children in a Grade III, Level A General Hospital andConsideration on Pharmaceutical Care

Application of Dexmedetomidine Combined with Hydromorphone Nasal Drip in Sedation of Mother-InfantSeparation before Adenoidectomy

Sirolimus in the Treatment of 5 Cases of Blue Rubber Bleb Nevus Syndrome in Children and Literature Review

Related Author

Wang Weina

Cheng Sheng

Wei Hongtao

Shen Su

Huang Zhizhuo

Huang Lin

Jia Yueping

Lu Aidong

Related Institution

Beijing Friendship Hospital, Capital Medical University

Peking University People’s Hospital

The Second People’ s Hospital of Anhui Wuhu, Anhui Wuhu

Jiangsu Taizhou People’s Hospital, Jiangsu Taizhou

Children’s Hospital Affiliated to Zhengzhou University,Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou Key Laboratory of Children’s Digestive Diseases

⁰